Compare LHX & A Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LHX | A |
|---|---|---|
| Founded | 1895 | 1999 |
| Country | United States | United States |
| Employees | 45000 | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Laboratory Analytical Instruments |
| Sector | Industrials | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 53.0B | 38.0B |
| IPO Year | 2002 | 1999 |
| Metric | LHX | A |
|---|---|---|
| Price | $286.67 | $145.97 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 15 |
| Target Price | ★ $353.80 | $161.47 |
| AVG Volume (30 Days) | 1.5M | ★ 1.7M |
| Earning Date | 04-30-2026 | 05-27-2026 |
| Dividend Yield | ★ 1.56% | 0.92% |
| EPS Growth | ★ 8.39 | 3.16 |
| EPS | ★ 5.85 | 2.27 |
| Revenue | ★ $6,182,000,000.00 | $4,472,000,000.00 |
| Revenue This Year | $8.25 | $8.45 |
| Revenue Next Year | $7.58 | $6.13 |
| P/E Ratio | ★ $49.49 | $62.27 |
| Revenue Growth | 4.78 | ★ 6.43 |
| 52 Week Low | $262.68 | $108.35 |
| 52 Week High | $379.23 | $160.27 |
| Indicator | LHX | A |
|---|---|---|
| Relative Strength Index (RSI) | 49.38 | 62.69 |
| Support Level | $285.27 | $141.22 |
| Resistance Level | $302.88 | $151.38 |
| Average True Range (ATR) | 8.85 | 3.68 |
| MACD | 0.11 | 0.19 |
| Stochastic Oscillator | 58.10 | 93.86 |
In addition to its legacy software-defined radio franchise, L3Harris Technologies has through a series of acquisitions established franchises producing uncrewed aerial vehicles, sensors, avionics, space-based systems, missiles, and solid rocket motors. It is also adept at refitting civilian aircraft for military use, provides military and commercial training services, and maintains the US Federal Aviation Administration's communications infrastructure.
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life science and diagnostic firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and diagnostics, cross lab operations consisting of consumables and services, and applied end markets. Over half of its sales are generated from the biopharmaceutical, chemical, and advanced materials end markets, which we view as the stickiest end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the US and China representing the largest country concentrations.